LobbyingAdvanced Medical Technology Assn lobbying by quarter
Advanced Medical Technology Assn's latest lobbying report covers Q2 2026, at $971K. The four quarters Q3 2025–Q2 2026 total $3.9M. Its first report covers Q4 2022; the issues it reports most are Budget/Appropriations and Health Issues.
Advanced Medical Technology Assn
- Latest quarter
- $971K
- Q2 2026 · 1 reports
- Last 12 months
- $3.9M
- Last 4 quarters
- vs last quarter
- −11.7%
- Q2 2026 against the quarter before
- First report
- Q4 2022
- The first quarter a report named it
Lobbying by quarter
| Quarter | Amount | Reports |
|---|---|---|
| Q4 2022 | $750K | 1 |
| Q1 2023 | $840K | 1 |
| Q2 2023 | $700K | 1 |
| Q3 2023 | $680K | 1 |
| Q4 2023 | $680K | 1 |
| Q1 2024 | $1M | 1 |
| Q2 2024 | $880K | 1 |
| Q3 2024 | $960K | 1 |
| Q4 2024 | $940K | 1 |
| Q1 2025 | $1M | 1 |
| Q2 2025 | $950K | 1 |
| Q3 2025 | $860K | 1 |
| Q4 2025 | $942K | 1 |
| Q1 2026 | $1.1M | 1 |
| Q2 2026 | $971K | 1 |
Policy issues the reports name
- Budget and appropriations15 reports
- Health issues15 reports
- Medicare and Medicaid15 reports
- Small business15 reports
- Taxation15 reports
- Trade15 reports
A report that names several issues counts once for each.
Who was lobbied
- Centers For Disease Control & Prevention (CDC)15 reports
- Centers For Medicare and Medicaid Services (CMS)15 reports
- Commerce, Dept of (DOC)15 reports
- Environmental Protection Agency (EPA)15 reports
- Food & Drug Administration (FDA)15 reports
- Health & Human Services, Dept of (HHS)15 reports
- HOUSE OF REPRESENTATIVES15 reports
- Natl Security Council (NSC)15 reports
- Office of Management & Budget (OMB)15 reports
- SENATE15 reports
- State, Dept of (DOS)15 reports
- U.S. Trade Representative (USTR)15 reports
- White House Office15 reports
- Treasury, Dept of5 reports
Firms it paid
| Firm | ||
|---|---|---|
| In-houseAdvanced Medical Technology Assn | $13.3M | 15 quarters |
Former officials lobbying for it
No lobbyist with a covered position.
Lobbying reports
| Filed by | ||
|---|---|---|
| 07/20for Q2 | In-house | $971K |
| 04/20for Q1 | In-house | $1.1M |
| 01/20for Q4 2025 | In-house | $942K |
| 25/10/17for Q3 2025 | In-house | $860K |
| 25/07/17for Q2 2025 | In-house | $950K |
| 25/04/21for Q1 2025 | In-house | $1M |
| 25/01/17for Q4 2024 | In-house | $940K |
| 24/10/21for Q3 2024 | In-house | $960K |
| 24/07/19for Q2 2024 | In-house | $880K |
| 24/04/20for Q1 2024 | In-house | $1M |
| 24/01/19for Q4 2023 | In-house | $680K |
| 23/10/20for Q3 2023 | In-house | $680K |
| 23/07/20for Q2 2023 | In-house | $700K |
| 23/04/20for Q1 2023 | In-house | $840K |
| 23/01/20for Q4 2022 | In-house | $750K |